Alex Ashenden

Dr. Alex Ashenden

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Biointerphases
Verified
Journal Article
Open access
PDF file
SKShinji Kihara
Shinji Kihara
AAAlex Ashenden
Alex Ashenden
MKManmeet Kaur
Manmeet Kaur
JGJudith Glasson
Judith Glasson
SGSunandita Ghosh
Sunandita Ghosh
DMDuncan J. McGillivray
Duncan J. McGillivray
Plastic waste is ubiquitously spread across the world and its smaller analogs—microplastics and nanoplastics—raise particular health concerns. While biological impacts of microplastics and nanoplastics have been actively studied, the chemical and biological bases for the adverse effects are sought after. This work explores contributory factors by combining results from in vitro and model mammalian membrane experimentation to assess the outcome of cell/nanoplastic interactions in molecular detail, inspecting the individual contribution of nanoplastics and different types of protein coronae. The in vitro study showed mild cytotoxicity and cellular uptake of polystyrene (PS) nanoplastics, with no clear trend based on nanoplastic size (20 and 200 nm) or surface charge. In contrast, a nanoplastic size-dependency on bilayer disruption was observed in the model system. This suggests that membrane disruption resulting from direct interaction with PS nanoplastics has little correlation with cytotoxicity. Furthermore, the level of bilayer disruption was found to be limited to the hydrophilic headgroup, indicating that transmembrane diffusion was an unlikely pathway for cellular uptake—endocytosis is the viable mechanism. In rare cases, small PS nanoplastics (20 nm) were found in the vicinity of chromosomes without a nuclear membrane surrounding them; however, this was not observed for larger PS nanoplastics (200 nm). We hypothesize that the nanoplastics can interact with chromosomes prior to nuclear membrane formation. Overall, precoating PS particles with protein coronae reduced the cytotoxicity, irrespective of the corona type. When comparing the two types, the extent of reduction was more apparent with soft than hard corona.

Verified
Journal Article
Open access
PDF file
AAAlex Ashenden
Alex Ashenden
ACAyesha Chowdhury
Ayesha Chowdhury
LALucy T. Anastasi
Lucy T. Anastasi
KLKhoa Lam
Khoa Lam
TRTomas Rozek
Tomas Rozek
KKKarin Kassahn
Karin Kassahn
Newborn screening programs have seen significant evolution since their initial implementation more than 60 years ago, with the primary goal of detecting treatable conditions within the earliest possible timeframe to ensure the optimal treatment and outcomes for the newborn. New technologies have driven the expansion of screening programs to cover additional conditions. In the current era, the breadth of screened conditions could be further expanded by integrating omic technologies such as untargeted metabolomics and genomics. Genomic screening could offer opportunities for lifelong care beyond the newborn period. For genomic newborn screening to be effective and ready for routine adoption, it must overcome barriers such as implementation cost, public acceptability, and scalability. Metabolomics approaches, on the other hand, can offer insight into disease phenotypes and could be used to identify known and novel biomarkers of disease. Given recent advances in metabolomic technologies, alongside advances in genomics including whole-genome sequencing, the combination of complementary multi-omic approaches may provide an exciting opportunity to leverage the best of both approaches and overcome their respective limitations. These techniques are described, along with the current outlook on multi-omic-based NBS research.

Verified
Journal Article
Open access
PDF file
AAAlex Ashenden
Alex Ashenden
TRTomas Rozek
Tomas Rozek
LALucy Anastasi
Lucy Anastasi
ACAyesha Chowdhury
Ayesha Chowdhury
KLKhoa Lam
Khoa Lam
KKKarin Kassahn
Karin Kassahn
Advances in metabolomics and genomics present new opportunities to expand newborn screening. Traditional screening approaches have relied on condition-specific biomarkers; however, untargeted metabolomic profiling may enable broader detection of genetic conditions. In this study, we developed and evaluated a novel metabolomic screening approach based on defining a reference profile representing a healthy newborn population. Retrospective dried blood spot samples from 2948 newborns were analysed using untargeted metabolomics and lipidomics, generating more than 30,000 features. A discovery cohort of over 2000 healthy newborns and newborns with genetic conditions was used to identify 1115 features that best discriminated between groups. These features formed the basis of a screening algorithm, which was subsequently evaluated in an independent validation cohort containing genetic conditions not represented in the discovery cohort. Across the discovery and validation cohorts, 180 cases representing 113 unique genetic conditions were assessed, including metabolic, haematological, neurological, and syndromic conditions. In the independent validation cohort, the algorithm achieved an area under the receiver operating characteristic curve of 0.799, with a specificity of over 99%. These findings demonstrate the potential of untargeted metabolomic profiling to identify newborns at increased risk of genetic disease and support future exploration in a multi-omic newborn screening design.